Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States
Authors:
- Jaime L. RubinJRJaime L. Rubin
- Lisa J. McGarryLMLisa J. McGarry
- David R. StruttonDSDavid R. Strutton
- Keith P. KlugmanKKKeith P. Klugman
- Stephen I. PeltonSPStephen I. Pelton
- Kristen E. GilmoreKGKristen E. Gilmore
- Milton C. WeinsteinMWMilton C. Weinstein
- 1 November 2010
- Vol. 28 (48) , 7634-7643
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate VaccineThe Journal of Infectious Diseases, 2010
- Effect of Pneumococcal Conjugate Vaccine on Pneumococcal MeningitisNew England Journal of Medicine, 2009
- Changing Epidemiology of Pneumococcal Meningitis after the Introduction of Pneumococcal Conjugate Vaccine in the United StatesClinical Infectious Diseases, 2008
- Trends in Acute Otitis Media-Related Health Care Utilization by Privately Insured Young Children in the United States, 1997–2004Pediatrics, 2008
- Health Care Utilization for Pneumonia in Young Children After Routine Pneumococcal Conjugate Vaccine Use in the United StatesArchives of Pediatrics & Adolescent Medicine, 2007
- Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysisThe Lancet, 2007
- National Impact of Universal Childhood Immunization With Pneumococcal Conjugate Vaccine on Outpatient Medical Care Visits in the United StatesPediatrics, 2006
- Cost-Effectiveness of Pneumococcal Conjugate VaccineThe Pediatric Infectious Disease Journal, 2006
- Cost-Effectiveness of Conjugate Meningococcal Vaccination Strategies in the United StatesPediatrics, 2005
- Projected Cost-effectiveness of Pneumococcal Conjugate Vaccination of Healthy Infants and Young ChildrenJAMA, 2000